Aurinia PharmaceuticalsAUPH
Market Cap: $1.03B
About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Employees: 300
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
47% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $6.94M
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
12% more capital invested
Capital invested by funds: $283M [Q1] → $316M (+$32.9M) [Q2]
0.19% less ownership
Funds ownership: 38.86% [Q1] → 38.68% (-0.19%) [Q2]
3% less funds holding
Funds holding: 174 [Q1] → 168 (-6) [Q2]
19% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 32
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Cantor Fitzgerald Olivia Brayer 62% 1-year accuracy 16 / 26 met price target | 39%upside $10 | Overweight Reiterated | 16 Sept 2024 |
Cantor Fitzgerald Olivia Brayer 62% 1-year accuracy 16 / 26 met price target | 39%upside $10 | Overweight Reiterated | 9 Sept 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 138 met price target | 81%upside $13 | Buy Reiterated | 6 Sept 2024 |
Financial journalist opinion
Based on 7 articles about AUPH published over the past 30 days